top of page

PROGRAMME 

08:30 – 09:00 - Gather together and On-site Registration

 

09:00 – 09:10 - Introduction

Sumathi Iyengar - Amir Kedar, WAS organizations and Fabio Candotti, CHUV, Lausanne, Switzerland

 

09:10 – 09:25 – Families Stories

Family story – Daniel Wheeler, UK, Young Adult post GT and HSCT story

09:25 – 09:55 - Plenary Session 1

Markus G. Seidel - Deputy Head of the Division of Pediatric Hematology-Oncology, Medical University Graz, Austria

 

"Malignancies in IEI/PID

 

09:55 – 10:50 - Research Session 1 

Chair: Lisa Westerberg (Karolinska Institute, Solna, Sweden)

09:55 - 10:10 Mo Li - King Abdullah University of Science and Technology, Saudi Arabia

“Beyond the Cytoskeleton: Isogenic iPSC Models Reveal New Mechanisms of Wiskott-Aldrich Syndrome”

10:10 - 10:25 Ismail Shakir - King Abdullah University of Science and Technology, Saudi Arabia

“WASP Regulates the Nucleolus and Macrophage Inflammatory Response via NPM1”

10:25 - 10:40 Lia G Pinho - Karolinska Institute, Solna, Sweden

“A systematic approach to understanding how patient variants affect the activity of Wiskott-Aldrich syndrome protein”

 

10:40 - 10:50 Questions & answers and discussion

 

10:50 – 11:10 – Break

 

11:10 – 11:40 - Plenary Session II

Loïc Dupre- co-head of team ‘Integrative Mapping of Lymphocyte Signaling and Function INFINITy’ Toulouse Institute for Infectious and Inflammatory Diseases – INSERM UMR 1291 – France

 

"WASP and co-actors as remodelers of the actin networks sustaining T cell function"

 

11:40 – 12:15 –Research Session 2 

Chair: Fabio Candotti (Lausanne University Hospital, Lausanne, Switzerland)

11:40 - 11:55 Rhaissa Calixto Vieira - Karolinska Intitute, Solna, Sweden

“Small compound PTW08 restores megakaryocyte and platelet production in Wiskott-Aldrich Syndrome”

 

11:55 - 12:10  Jordan Chill - Bar Ilan University, Israel

“A Molecular View of WAS Protein in Health and Disease: The Case of Hotspot Mutation R86C”           

12:10 - 12:15 Questions & answers and discussion

 

12:15 – 12:50 – Gene Therapy Session 

Chair: Anna Villa (San Raffaele Hospital, Milan, Italy)

12:15 - 12:30 Sabina Cenciarelli - San Raffaele Hospital, Milan, Italy
“Megakaryocytes alterations and Thrombopoietin levels in patients affected by Wiskott-Aldrich Syndrome before and after Gene Therapy with Etuvetidigene Autotemcel”

 

12:30 - 12:45 Michaela Semeraro - Hôpital Necker Enfants malades APHP, Paris, France

“Incomplete myeloid correction drives late IL-1–sensitive inflammation after WAS Gene Therapy”

12:45 - 12:50 Questions & answers and discussion

 

12:50 – 14:00 - Lunch

 

14:00 – 14:15 – Families Story

Family story – Alon Cand, Israel. Young Adult Future decision-making considerations  

 

14:15 – 14:45– Gene Therapy Panel

Chair: Michael Albert (DKNS, Munich, Germany)

“Challenges of extending access to gene therapy for WAS”

 

Participants: Alessandro Aiuti, Francesca Ferrua, Fabio Candotti, Sumathi Iyengar, Martine Pergent, Telethon representative.

 

14:45 – 15:15 - Plenary Session C

Fabio Candotti - CHUV, Lausanne, Switzerland

 

“IgA nephropathy and WAS”

 

15:15 – 16:25 –Clinical Session 1 

Chair: Francesca Ferrua (San Raffaele Hospital, Milan, Italy)

 

15:15 - 15:30 Maja Stojanović – President, Serbian Group for Primary Immunodeficiencies, University of Belgrade, Belgrade, Serbia. (Invited speaker)

“Challenges of diagnosing and treating Wiskott-Aldrich Syndrome (WAS) in resource-constrained settings”.

 

15:30 - 15:45 Annarosa Soresina - University of Brescia, ERN Rita Center, Brescia, Italy

“Retrospective-Prospective immunological study of Class I and Class II Wiskott- Aldrich patients”

 

15:45 - 16:00 Anna Ogneva - Dmitry Rogachev National Medical and Research Center of Pediatric

Hematology, Oncology and Immunology, Moscow, Russia

“Thrombopoietin receptor agonists (TPO-RA) and spleen tyrosine kinase inhibitor (SYKi) for the treatment of thrombocytopenia in Wiskott-Aldrich syndrome (WAS) patients”

16:00 - 16:15 Lea Makhlouf - Necker-Enfants Malades Hospital, AP-HP, Paris,

“Nearly Two Decades of Allogeneic HSCT for Wiskott-Aldrich Syndrome: A Single-Center Experience”

16:15 - 16:25 Questions and answers and discussion

 

16:25 – 16:45 –Break

 

16:45 – 17:35 –Clinical Session 2 

Chair: Carmem Bonfim (Pediatric Transplant and Cellular Therapy Program, Duke University, Durham, NC, USA)

16:45 - 17:00

Monirujjaman Biswas - National Institute of Respiratory Diseases, New Delhi, India.

“Early Identification, Clinical Outcomes and Predictors of Autoimmune Complications in Wiskott–Aldrich Syndrome”

 

17:00 - 17:15 Deepti Suri - Postgraduate Institute of Medical Education and Research, Chandigarh, India.

“Renal injury in patients with Wiskott Aldrich Syndrome: an underrecognized entity”

 

17:15 - 17:30  Tinsae AlemayehuPediatrics and Adolescent Health, Gaborone, Botswana

“A first report of experience in managing children with Wiskott-Aldrich syndrome in Ethiopia”

17:30 - 17:35 Questions and answers and discussion

 

17:35 – 18:05 - Clinical Session Panel

Chair: Anders Fasth (Sweden)

“Delphi Consensus statement for WAS”

Participants: Fabio Candotti, Alessandro Aiuti, Michael Albert, Sumathi Iyengar

18:05– 18:15 – Closing and Summary of the day

Fabio Candotti, Michael Albert, Francesca Ferrua, Lisa Westerberg

 

18:15 – 19:00 – Reception

An informal get-together to renew acquaintances and meet new colleagues will be held at the Meeting Venue.

All registered participants are invited to join.

“Thrombopoietin receptor agonists (TPO-RA) and spleen tyrosine kinase inhibitor (SYKi) for the treatment of thrombocytopenia in Wiskott-Aldrich syndrome (WAS) patients”

© 2025 by WAS2026.ORG

bottom of page